Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Doxorubicin Market, by Application
6.1 Introduction
6.2 Liver cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3 Gastric cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4 Breast cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.5 Bone sarcoma
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.6 Prostate cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.7 Stomach Cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.8 Ovarian cancer
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.9 Leukemia
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.10 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 7. Global DoxorubicinMarket, by Distribution Channel
7.1 Introduction
7.2 Hospital pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3 Retail pharmacy
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4 Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
Chapter 8. Global Doxorubicin Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 Latin America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 Middle East
8.5.2 Africa
Chapter 9. Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
Chapter 10. Company Profiles
10.1 Pfizer, Inc.
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Sun Pharmaceutical Industries Ltd..
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Janssen Pharmaceuticals
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Accord Healthcare.
10.4.1 Company Overview
10.4.2 Technologys/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Novartis AG.
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Sandoz.
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Dr. Reddy’s Laboratories Ltd.
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financial Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Teva Pharmaceuticals
10.8.1 Overview
10.8.2 Treatment Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 GLENMARK PHARMACEUTICALS LTD.
10.9.1 Overview
10.9.2 Treatment Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Others.
10.10.1 Overview
10.10.2 Treatment Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
Chapter 11. Appendix
LIST OF TABLES
Table 1 Global Doxorubicin Market Synopsis, 2020-2027
Table 2 Global Doxorubicin Market Estimates and Forecast, 2020-2027 (USD Million)
Table 3 Global Doxorubicin Market, by Region, 2020-2027 (USD Million)
Table 4 North America: DoxorubicinMarket, by Application, 2020-2027 (USD
Million)
Table 5 North America: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD
Million)
Table 6 US: Doxorubicin Market, by Application , 2020-2027 (USD Million)
Table 7 US: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD Million)
Table 8 Canada: Doxorubicin Market, by Application, 2020-2027 (USD
Million)
Table 9 Canada: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD
Million)
Table 10 South America: Doxorubicin Market, by Application, 2020-2027 (USD
Million)
Table 11 South America: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD
Million)
Table 12 Europe: Doxorubicin Market, by Application, 2020-2027 (USD Million)
Table 13 Europe: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD Million)
Table 14 Western Europe: Doxorubicin Market, by Application, 2020-2027
(USD Million)
Table 15 Western Europe: Doxorubicin Market, by Distribution Channel, 2020-2027
(USD Million)
Table 16 Eastern Europe: Doxorubicin Market, by Application, 2020-2027
(USD Million)
Table 17 Eastern Europe: Doxorubicin Market, by Distribution Channel, 2020-2027
(USD Million)
Table 18 Asia-Pacific: Doxorubicin Market, by Application, 2020-2027 (USD
Million)
Table 19 Asia-Pacific: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD
Million)
Table 20 Middle East & Africa: Doxorubicin Market, by Application, 2020-2027
(USD Million)
Table 21 Middle East & Africa: Doxorubicin Market, by Distribution Channel, 2020-2027
(USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Doxorubicin Market
Figure 3 Segmentation Market Dynamics for Global Doxorubicin Market
Figure 4 Global Doxorubicin Market Share, by Application, 2020
Figure 5 Global Doxorubicin Market Share, by Distribution Channel, 2020
Figure 6 Global Doxorubicin Market Share, by Region, 2020
Figure 7 North America: Doxorubicin Market Share, by Country, 2020
Figure 8 Europe: Doxorubicin Market Share, by Country, 2020
Figure 9 Asia-Pacific: Doxorubicin Market Share, by Country, 2020
Figure 10 Middle East & Africa: Doxorubicin Market Share, by Country, 2020
Figure 11 Global Doxorubicin Market: Company Share Analysis, 2020 (%)
Figure 12 Pfizer, Inc: Key Financials
Figure 13 Pfizer, Inc: Segmental Revenue
Figure 14 Pfizer, Inc: Geographical Revenue
Figure 15 Sun Pharmaceutical Industries Ltd.: Key Financials
Figure 16 Sun Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 17 Sun Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 18 Janssen Pharmaceuticals: Key Financials
Figure 19 Janssen Pharmaceuticals: Segmental Revenue
Figure 20 Janssen Pharmaceuticals: Geographical Revenue
Figure 21 Accord Healthcare.: Key Financials
Figure 22 Accord Healthcare.: Segmental Revenue
Figure 23 Accord Healthcare.: Geographical Revenue
Figure 24 Novartis AG
Figure 25 Sandoz
Figure 26 Dr. Reddy’s Laboratories Ltd.
Figure 27 Teva Pharmaceuticals
Figure 28 GLENMARK PHARMACEUTICALS LTD
Doxorubicin Market Scenario
Doxorubicin market valued for USD 916.5 million and expected to register steady growth rate of 6.5% during the forecast period.
$916.5 million
Market Size
6.5%
CAGR
North America
Dominating Region
2022-2030
Forecast Period
Segmentation
Key Players
- Pfizer Inc
- Sun Pharmaceutical Industries Ltd.
- Janssen Pharmaceuticals
- Accord Healthcare
- Novartis AG
- Sandoz
- Reddy’s Laboratories Ltd.
- Teva Pharmaceuticals
- GLENMARK PHARMACEUTICALS LTD.
Drivers
- Geriatric population and the growing prevalence of cancer
- Increasing awareness programs for cancer treatment
Doxorubicin Market Overview
The doxorubicin market accounts for USD 916.5 million in 2017 and expected to register steady growth rate of 6.5% during the forecast period. Doxorubicin is the generic drug used to treat cancer chemotherapy drugs Adriamycin and Rubex. It is an anthracycline antibiotic and belongs to the anti-cancer group of anti-cancer. The medications are antineoplastic and are made from the natural product produced by the bacterium Streptomyces peucetius var. caesius. Doctors use this for the treatment of different types of cancer. The cancers that can be treated through this are breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms' tumour, Hodgkin's, and non-Hodgkin's lymphomas. Less commonly, it is also used to treat squamous cell carcinomas of the head and neck. Vagina and cervix, multiple refractory myeloma, and neuroblastoma. Doxorubicin slows down the proliferation rate of cancerous cells by intercalating between the base pairs in the DNA helix. And this can prevent DNA replication and inhibit protein synthesis. The market is facing good growth due to several reasons. One of the major reasons is the rise in cancer patients worldwide, which is the main cause of death. The lifestyle that people are adopting, which causes more cancer cells in the body, is another cause of the growth.
Segmentation
The doxorubicin market has been segmented on the basis of application, and distribution channel.
The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.
The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.
The doxorubicin market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The doxorubicin market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Doxorubicin Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The Americas are expected to dominate the doxorubicin market owing to the growing pool of cancer patients associated with increasing elderly population, strong presence of major manufacturers in the region, and adoption of advanced healthcare facilities coupled with increased awareness about cancer treatment in general population. In 2016, according to the National Cancer Institute in United states approximately USD 147.3 billion were spend for cancer care and around 15.5 million new cases of cancer were registered.
The European market is expected to be the second-largest doxorubicin market. The market growth in this region can be attributed to the growing prevalence of cancer along with rising healthcare expenditure is expected to drive the growth of the market. In 2016, according to European commission, the European nations invested 16.2% of its total expenditure on healthcare.
Asia-Pacific is expected to be the fastest-growing doxorubicin market during the forecast period owing to the continuously increasing investment in healthcare, increasing geriatric population in the region, and increasing opportunities for various manufacturers. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), 12.4% of the total Asian population is 60 or above 60-year-old and by 2050 one third of the population will cross 60 year.
The market in the Middle East & Africa is expected to account for the smallest share of the doxorubicin market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Market of Doxorubicin, by Application
- Liver cancer
- Gastric cancer
- Breast cancer
- Bone sarcoma
- Prostate cancer
- Stomach Cancer
- Ovarian cancer
- Leukemia
- others
Market of Doxorubicin, by Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
Market of Doxorubicin, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Company Profiles
- Pfizer, Inc
- Sun Pharmaceutical Industries Ltd.
- Janssen Pharmaceuticals
- Accord Healthcare
- Novartis AG
- Sandoz
- Reddy’s Laboratories Ltd.
- Teva Pharmaceuticals
- GLENMARK PHARMACEUTICALS LTD.
Recent Development
April 2022
The research group of the University of Manitoba in Canada found that vitamin C improved markers of heart health and survival in rats given doxorubicin, mainly by reducing oxidative stress and inflammation. The new study assessed whether vitamin C could similarly help prevent doxorubicin's adverse effects on skeletal muscle.
The research found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte apoptosis and mitochondrial dysfunction induced by Dox treatment.
May 2022
A team of researchers from the National University of Singapore (NUS) is best for novel magnetic therapy. This is delivered using the OncoFTX System, which serves as an effective companion therapy to chemotherapy to enhance treatment outcomes for breast cancer.
Intended Audience
- Doxorubicin manufacturing suppliers and companies
- Healthcare providers
- Research institutes and academic centers
- Contract manufacturing organizations (CMOs)
- Market research and consulting
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2017 : USD 916.5 million |
| CAGR | 6.5% (2018 - 2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Application, Distribution Channel |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Doxorubicin market are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK PHARMACEUTICALS LTD. and various others |
| Key Market Opportunities | Strategic alliances, mergers and acquisitions and new product developments |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The global doxorubicin market was valued at USD 916.5 million in 2017.
The global doxorubicin market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2018 to 2023.
The global doxorubicin market is primarily driven by the growing geriatric population and the growing prevalence of cancer.
The leading regional market for doxorubicin is the Americas, followed by Europe.
Leading players in the doxorubicin market include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Reddy’s Laboratories Ltd., and Teva, among others.
